（シアトル・チルドレンズ）PD-L1：CD3二特異性T細胞エンゲージャーが、難治性の原発性および転移性頭蓋内腫瘍を強力に死滅させる

要旨

Central nervous system (CNS) tumors represent a large unmet medical need. Many pediatric and adult brain cancers and other cancers (e.g., lung, colon, breast) with CNS involvement remain largely intractable despite standard of care and advanced treatment strategies. We engineered a bispecific PD-L1:CD3 T-cell engager (TCE) and discovered promising efficacy in a wide range of pre-clinical intracranial tumor models, including some models with intact blood brain barriers.